Cytotoxic T lymphocyte antigen (CTLA) 4 and programmed cell death receptor (PD) 1 have led to previously detected therapeutic responses in melanomas and non-small cell lung cancer (NSCLC) [21,22,23,24,25,26,27,28]. This evidence concerns the gene RPL17 and non-small cell lung carcinoma.